A Two-Way Path to Health: Environmental Influences on Skeletal Muscle Endocrine Function

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age35-75
SponsorPoznan University of Physical Education

About this trial

Given the well-established anti-inflammatory and health-promoting effects of physical activity as a non-pharmacological intervention, an important question remains whether different types of exercise differ in their ability to reduce the body burden of per- and polyfluoroalkyl substances (PFAS) and whether PFAS exposure modifies exercise-induced adaptive responses. The investigators hypothesize that the coexistence of physical inactivity, overweight/obesity, reduced muscle mass, and consequently lower concentrations of myokines/exerkines contributes to impaired cardiovascular function, reduced exercise capacity, and a greater PFAS body burden. Collectively, these factors may adversely affect work ability, reduce occupational participation, and discourage continued employment among middle-aged women. In the context of unfavorable demographic trends, such consequences may represent a significant economic burden for society.

The primary objective of this project is to determine whether baseline PFAS concentrations are associated with the health status of women entering the study and to characterize circulating profiles of myokines/exerkines and arginine metabolites. A secondary objective is to compare the effects of different exercise programs on PFAS concentrations and their potential elimination from the body. In addition, we will investigate whether a history of cancer treatment, despite increasingly favorable clinical outcomes, is associated with long-term alterations in skeletal muscle endocrine function, myokine and exerkine release, and PFAS body burden.

The study will include perimenopausal women. Participants will be allocated to one of two supervised exercise programs: high-intensity circuit training (HICT) or interval walking training (IWT). Both interventions will last six months and will be performed two times per week (with possible additional unit performed at home). This period will be followed by six months of unsupervised maintenance training. Two additional groups will be included: a control group maintaining their usual lifestyle and a group of women who have completed cancer treatment. Participants in the oncology group will be instructed to maintain a daily physical activity level of approximately 7,000-10,000 steps.

Assessments will be performed at baseline, immediately after the intervention, and six months after its completion. Circulating concentrations of selected myokines, exerkines, arginine metabolites, and 18 PFAS compounds will be measured in blood, while PFAS concentrations will also be determined in urine samples. Cardiorespiratory fitness, body composition assessed by dual-energy X-ray absorptiometry (DXA), dietary habits, quality of life, and health literacy will also be evaluated.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Women,

aged 35-75 years

qualified by a physician for participation in the study and with no contraindications to the training intervention (e.g., heart failure, asthma, chronic obstructive pulmonary disease [COPD], or arthritis)

Women ,

Disqualifiers

history of cardiovascular disease,

previous hospitalization for cardiovascular conditions,

ongoing cardiovascular treatment, or recent cardiovascular symptoms,

advanced osteoporosis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Experimental: IWT- Interval Walking Training

    Other intervention

    Interval Walking Training will consist of five repetitions of alternating 3-minute intervals of fast and slow walking, resulting in a total exercise duration of 30 minutes per session. The training period will last 6 months, two training session/a week.

  • Exercise training II

    Other intervention

    HICT training will consist of ten exercises: jumping jacks, push-ups, abdominal crunches, squats, planks, triceps dips using a chair, high knees (running in place), lunges, push-ups with rotation, and side planks. Each exercise will be performed for 30 seconds, followed by a 10-second transition period. A 2-minute rest period will be provided between sets. Training period will last 6 monts /a two training session a week

  • Walking

    Other intervention

    Walking training is addressed to breast cancer patients who have already finished onco-treatment. Participants will be instructed to maintain a daily step count of 7,000-10,000 steps throughout the study period.

Treatment groups

300 Participants
are divided into 4 treatment groups
Group A: Control GroupNo intervention 0 interventions
Group B: IWT- Interval Walking TrainingExperimental treatment 1 intervention
Group C: HICT-High Intensity Circuit TrainingExperimental treatment 1 intervention
Group D: Onco-female groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Blood Cell Counts (×10⁹/L)

Blood Cell Counts (×10⁹/L): White Blood Cell Count (WBC), Platelet Count (PLT), Neutrophil Count (NEUT), Lymphocyte Count (LYMPH), Monocyte Count (MONO), Eosinophil Count (EOS), and Basophil Count (BASO) will be determined using standard analytical method.

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
2

Leukocyte Differential Percentages (%)

The percentages (%) of neutrophils (NEUT), lymphocytes (LYMPH), monocytes (MONO), eosinophils (EOS), and basophils (BASO) will be determined as part of the complete blood count with differential.

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
3

Red Blood Cell Count (RBC)

Red Blood Cell Count (×10¹²/L)

Time frame
At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
4

Blood Concentrations

Blood Concentrations (g/dL): Hemoglobin Concentration (HGB) and Mean Corpuscular Hemoglobin Concentration (MCHC).

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"

Secondary outcomes

1

Oxygen uptake at rest, at anaerobic threshold and maximal intensity

Oxygen uptake will be measured and expressed in absolute VO₂ L·min-¹ values

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
2

Oxygen uptake at rest, at anaerobic threshold and maximal intensity

Description: Oxygen uptake will be measured and expressed in relative VO₂ mL·min-¹ kg-¹ values.

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
3

Heart Rate

Resting and maximal Heart Rate (beats/min). This outcome will be measured during the Ramp test.

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"
4

Body Height

Body Height (m) is measured using Digital stadiometer (Seca 285, SECA, Hamburg, Germany).

Time frame
"At day 1" "after 6 months on day 1" "On average, in 1 year from day 1"

Other outcomes

1

Socio-demographic characteristics

Socio-demographic characteristics are collected with study-specific questionnaires.

Time frame
On day 1
2

Clinical history

Only for Onco-group clinical history will be collected with study-specific questionnaires and medical records.

Time frame
On day 1

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: